The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Innovative therapies for neovascular age-related macular degeneration
Abstract
Introduction: Investigational anti-VEGF treatments for neovascular age-related macular degeneration (nAMD) aim to improve visual outcomes and reduce treatment burden; these include long-acting agents, combination strategies, topical agents, sustained-release, and genetic therapies.Areas covered: The authors provide a comprehensive review of investigational therapies for nAMD, focusing on therapies currently in clinical trial.Expert opinion: Long-acting anti-VEGF agents have demonstrated promising results in phase 3 studies, and include Brolucizumab, a single-chain antibody fragment, and Abicipar, a designed ankyrin repeat protein (DARPin). Other unique anti-VEGF agents in current trials include Conbercept – a fusion protein of the VEGF receptor domains, KSI-301 – an anti-VEGF antibody biopolymer conjugate, and OPT-302 – an inhibitor of VEGF-C/D. Strategies to activate the Tie-2 receptor, some in combination with VEGF inhibition, are of interest, with recent trials of Faricimab, ARP-1536, and nesvacumab. Topical anti-VEGF ± anti-PDGF agents, such as pazopanib, squalamine lactate, regorafenib, and LHA510 have shown limited efficacy and/or have not been advanced, although PAN-90806 continues to advance with promising initial results. Sustained-release anti-VEGF treatments, to address treatment burden, include the ranibizumab Port Delivery System, GB-102, NT-503, hydrogel depot, Durasert, and ENV1305. Similarly, genetic therapies, including RGX-314 and ADVM-022, aim to provide sustained anti-VEGF expression from the retina.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Repeated intravitreal (IVT) injections of anti-VEGF therapies effectively slow vision loss in the majority of treatment-compliant patients with wet AMD. 7 – 13”
From Design and Characterization of a Novel Intravitreal Dual-Transgene Genetic Medicine for Neovascular Retinopathies (2024) · cites this paper as [13]
In the citing paper
“However, the requirement for lifelong injections imposes a substantial burden on patients and caregivers, and many patients fail to maintain initial therapeutic benefits owing to noncompliance with the burdensome treatment regimen. 3 , 7 , 8 , 10 , 13 – 20”
From Design and Characterization of a Novel Intravitreal Dual-Transgene Genetic Medicine for Neovascular Retinopathies (2024) · cites this paper as [13]
Citations
Cites
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886 · cited 1×
“and in most European Union countries), and 2/3 or more do not achieve a VA gain of 3 or more ETDRS lines [8,9].”
BackgroundVascular Endothelial Growth Factor Is a Secreted Angiogenic Mitogen
Leung, D. W., Cachianes, G., Kuang, W.-J., Goeddel, D. V., & Ferrara, N. (1989) · Science · doi:10.1126/science.2479986 · Cited by 4,986
Tumor Cells Secrete a Vascular Permeability Factor That Promotes Accumulation of Ascites Fluid
Senger, D. R., Galli, S. J., Dvorak, A. M., Perruzzi, C. A., Harvey, V. S., & Dvorak, H. F. (1983) · Science · doi:10.1126/science.6823562 · Cited by 3,972
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522 · cited 1×
“study demonstrated superiority of anti-VEGF-A injections over photodynamic therapy for preserving and recovering VA [86].”
BackgroundIntravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration
Heier, J. S., Brown, D. M., Chong, V., Korobelnik, J.-F., Kaiser, P. K., Nguyen, Q. D., Kirchhof, B., Ho, A., Ogura, Y., Yancopoulos, G. D., et al. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.09.006 · Cited by 2,485
Endothelial/Pericyte Interactions
Armulik, A., Abramsson, A., & Betsholtz, C. (2005) · Circulation Research · doi:10.1161/01.res.0000182903.16652.d7 · Cited by 2,048
Gerber, H.-P., McMurtrey, A., Kowalski, J., Yan, M., Keyt, B. A., Dixit, V., & Ferrara, N. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.46.30336 · Cited by 1,981
Hellström, M., Kalén, M., Lindahl, P., Abramsson, A., & Betsholtz, C. (1999) · Development · doi:10.1242/dev.126.14.3047 · Cited by 1,700
Benjamin, L. E., Hemo, I., & Keshet, E. (1998) · Development · doi:10.1242/dev.125.9.1591 · Cited by 1,265
Age-Related Macular Degeneration and Blindness due to Neovascular Maculopathy
Ferris, F. L., Fine, S. L., & Hyman, L. (1984) · Archives of Ophthalmology · doi:10.1001/archopht.1984.01040031330019 · Cited by 1,093
Research works printed but not linked: 12
- Hjelmqvist L, 2011, J Ophthalmol, 405724
- Rakic JM, 2013, Clin Ophthalmol, 7, 1849
- Davis S, 1999, Curr Top Microbiol Immunol, 237, 173
- Dugel PU, 2018, Phase 3, randomized, double-masked, multicenter trials of brolucizumab vs. aflibercept for neovascular AMD: ninety-six-week results from the HAWK and HARRIER studies
- Dugel PU, 2017, HAWK & HARRIER: 48-week results of 2 multi-centered, randomized, double-masked trials of brolucizumab versus aflibercept for neovascular AMD
- Boyer DS, 2016, Aflibercept combination therapies: rinucumab/aflibercept and nesvacumab/aflibercept
- Helzner J, 2018, Retin Physician
- Khanani AM, 2018, Simultaneous inhibition of VEGF and Ang-2 with faricimab in neovascular AMD: STAIRWAY phase 2 results
- Rubio RG., 2014, Retina Today
- 2018, LADDER trial of the port delivery system for ranibizumab: preliminary study results
- Lurker N., 2016, Ophthalmic Innoviations Summit at American Academy of Ophthalmology meeting
- Moja L, 2014, Cochrane Database Syst Rev, 15, CD011230
Cited by
Mettu, P. S., Allingham, M. J., & Cousins, S. W. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100906 · Cited by 370
Diabetic Macular Edema: Current Understanding, Molecular Mechanisms and Therapeutic Implications
Zhang, J., Zhang, J., Zhang, C., Zhang, J., Gu, L., Luo, D., & Qiu, Q. (2022) · Cells · doi:10.3390/cells11213362 · Cited by 300
“ARP-1536 is intravitreally administered, currently undergoing preclinical studies [161].”
BackgroundLutein and Zeaxanthin and Their Roles in Age-Related Macular Degeneration—Neurodegenerative Disease
Mrowicka, M., Mrowicki, J., Kucharska, E., & Majsterek, I. (2022) · Nutrients · doi:10.3390/nu14040827 · Cited by 299
“The effects of the inhibition of other growth factors, such as angiopoietin (Faricimab) [97], the use of a Port Delivery System (PDS) with ranibizumab [98], or gene therapy [99] are being tested.”
MethodOxidative Stress and Antioxidants in Age-Related Macular Degeneration
Kushwah, N. S., Bora, K., Maurya, M., Pavlovich, M. C., & Chen, J. (2023) · Antioxidants · doi:10.3390/antiox12071379 · Cited by 160
Khan, M., Aziz, A. A., Shafi, N., Abbas, T., & Khanani, A. M. (2020) · Cells · doi:10.3390/cells9081869 · Cited by 143
“By simultaneously binding to both targets, faricimab can provide improved efficacy and durability in patients with DME and durability in nAMD—inherently decreasing treatment burden [59,60], a targeted area of focus for researchers and ophthalmologists.”
Background
Metadata
- Authors
- Al-Khersan, H., Hussain, R. M., Ciulla, T. A., & Dugel, P. U.
- Affiliations
- University of Miami (US)
- Clearside Biomedical (United States) (US)
- University of Southern California (US)
- Corresponding author
- Hussain, Rehan M.
- Venue
- Expert Opinion on Pharmacotherapy
- Publisher
- Informa UK Limited
- Published
- 2019-07-12
- Volume
- 20
- Issue
- 15
- Pages
- 1879-1891
- ISSN
- 1465-6566 (ISSN-L)
- 1744-7666
- OpenAlex
- W2962115070
- Cited by
- 114
- References
- 69
- Citations by year
- 2026: 5 · 2025: 9 · 2024: 11 · 2023: 13 · 2022: 21 · 2021: 28 · 2020: 24 · 2019: 3
- FWCI
- 3.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Expert Opinion on Pharmacotherapy (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Heidelberg Engineering
- Allergan
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Keywords
- neovascular age-related macular degeneration, anti-VEGF therapy, brolucizumab, conbercept, faricimab, sustained drug release, gene therapy, visual outcome
- MeSH terms
- Aged, Aged, 80 and over, Humans, Macular Degeneration, Angiogenesis Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Innovative therapies for neovascular age-related macular degeneration. https://app.cochat.ai/papers/10.1080/14656566.2019.1636031
- The paper
- Al-Khersan, H., Hussain, R. M., Ciulla, T. A., & Dugel, P. U. (2019). Innovative therapies for neovascular age-related macular degeneration. Expert Opinion on Pharmacotherapy. https://doi.org/10.1080/14656566.2019.1636031
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.